코미팜
Financials
Valuation Metrics
코미팜's Market Cap is ₩7268B. At end of 2025 it was ₩5238B. Ranked #374 of 2,421 in KR market (top 15%), #123 of 1,640 on KOSDAQ (top 8%), #41 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 18%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 726.78B KRW | KR#374/2,421 Sec#41/231 |
| Revenue | 53.02B KRW | KR#1,753/2,421 Sec#118/231 |
| Net Income | -3.42B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 139.12B KRW | KR#1,559/2,421 Sec#121/231 |
| Net Assets | 74.16B KRW | KR#1,635/2,421 Sec#133/231 |
| Employees | 163 | KR#1,253/2,421 Sec#103/231 |
| Value | ||
| P/B | 9.80x | KR#2,351/2,421 Sec#209/231 |
| P/S | 13.71x | KR#2,307/2,421 Sec#170/231 |
| EV/EBITDA | 423.08x | KR#1,552/2,421 Sec#109/231 |
| FCF Yield | -0.51% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -4.61% | KR#1,788/2,421 Sec#129/231 |
| ROA | -2.46% | KR#1,788/2,421 Sec#126/231 |
| Op. Margin | 3.33% | KR#1,196/2,421 Sec#87/231 |
| Revenue Growth | -3.27% | KR#1,697/2,421 Sec#163/231 |
| Financial Health | ||
| Debt Ratio | 87.59% | KR#1,437/2,421 Sec#168/231 |
| Total Debt | 40.75B KRW | KR#1,087/2,421 Sec#76/231 |
| FCF | -3.71B KRW | KR#1,434/2,421 Sec#112/231 |
| Cash | 21.36B KRW | KR#1,212/2,421 Sec#86/231 |
| Current Ratio | 1.31x | KR#1,384/2,421 Sec#145/231 |
| Net Debt/EBITDA | 10.99x | KR#1,248/2,421 Sec#90/231 |
| Performance | ||
| 1Y Return | 45.16% | KR#287/2,421 Sec#17/231 |
| 1M Return | 4.73% | KR#769/2,421 Sec#56/231 |
| From 52W High | -9.73% | KR#67/2,421 Sec#3/231 |
| 1Y MDD | -35.21% | KR#415/2,421 Sec#30/231 |
| Trading | ||
| Volume | 158,754 shares | KR#563/2,421 Sec#38/231 |
| Trading Value | 1.54B KRW | KR#609/2,421 Sec#60/231 |
| Foreign Own. | 3.94% | KR#1,061/2,421 Sec#95/231 |
| Per Share | ||
| EPS | -46 KRW | KR—/2,421 Sec—/231 |
| BPS | 994 KRW | KR#2,308/2,421 Sec#211/231 |
Company Info
Established in 1972 for animal pharmaceutical manufacturing and sales, the company was listed on KOSDAQ in 2001 and produces vaccines and therapeutics at its Siheung-si and Yesan-gun factories. It engages in animal pharmaceutical manufacturing and offers virus and genetic testing research services, conducting overseas business through its subsidiaries. The company expanded its business areas by developing the new drug COMINOX, completing its Osong Bio-complex factory, and obtaining KGMP approval. It is now focused on global sales through a multinational pipeline. COMI Pharm was established in 1972 and is headquartered in Siheung-si, Gyeonggi-do.